Organization & Developments: Morphic

Parents

2021: Morphic: Pioneering Integrin Medicines
2023: Morphic Holding: The Price Drop Is Very Interesting
2023: Morphic Loses Another Big Pharma as J&J Bails on Research Deal
2024: Lilly inks $3.2B Morphic buyout to snag oral rival to Takeda's IBD blockbuster
Morphic believes oral drugs targeting the integrin protein family can transform the treatment paradigm for patients suffering from serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, as well as fibrosis and cancer.
Morphic Therapeutic is leading the development of a new generation of oral integrin drugs, informed by decades of world-leading expertise and a unique integrin discovery platform.